Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Pharmaust Limited ( (AU:NUZ) ) has shared an announcement.
Neurizon Therapeutics Limited, formerly known as PharmAust Limited, reported a significant increase in other income and a substantial rise in losses for the half-year ended 31 December 2024. The company experienced an increase in net assets, yet its loss from ordinary activities and overall loss rose dramatically, indicating challenging financial circumstances. The acquisition of Neurizon Therapeutics LLC highlights a shift in control within the company.
More about Pharmaust Limited
YTD Price Performance: -23.08%
Average Trading Volume: 5,882
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €38.74M
See more data about NUZ stock on TipRanks’ Stock Analysis page.